{"id":"NCT01604265","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis","officialTitle":"A Double Blind, Randomised, Parallel Group, Placebo Controlled Study of Sativex in the Treatment of Central Neuropathic Pain in Multiple Sclerosis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-03","primaryCompletion":"2002-08","completion":"2002-08","firstPosted":"2012-05-23","resultsPosted":"2012-09-19","lastUpdate":"2023-01-10"},"enrollment":66,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis","Neuropathic Pain"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Sativex","otherNames":["GW-1000-02"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Sativex","type":"EXPERIMENTAL"}],"summary":"To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.","primaryOutcome":{"measure":"Change From Baseline in the Mean Pain 0-10 Numerical Rating Scale Score at the End of Treatment (4 Weeks)","timeFrame":"0 - 4 weeks","effectByArm":[{"arm":"Sativex","deltaMin":-2.7,"sd":1.91},{"arm":"Placebo","deltaMin":-1.4,"sd":1.65}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":17},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["16186518"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["Dizziness","Nausea","Fall","Headache not otherwise specified","Dry Mouth"]}}